Literature DB >> 28903531

Local field radiotherapy without elective nodal irradiation for postoperative loco-regional recurrence of esophageal cancer.

Takuya Kimoto1, Hideya Yamazaki1, Gen Suzuki1, Norihiro Aibe1, Koji Masui1, Kotoha Tatekawa1, Naomi Sasaki1, Hitoshi Fujiwara2, Atsushi Shiozaki2, Hirotaka Konishi2, Satoaki Nakamura3, Kei Yamada1.   

Abstract

BACKGROUND: Radiotherapy is an effective treatment for the postoperative loco-regional recurrence of esophageal cancer; however, the optimal treatment field remains controversial. This study aims to evaluate the outcome of local field radiotherapy without elective nodal irradiation for postoperative loco-regional recurrence of esophageal cancer.
METHODS: We retrospectively investigated 35 patients treated for a postoperative loco-regional recurrence of esophageal cancer with local field radiotherapy between December 2008 and March 2016. The median irradiation dose was 60 Gy (range: 50-67.5 Gy). Thirty-one (88.6%) patients received concurrent chemotherapy.
RESULTS: The median follow-up period was 18 months (range: 5-94 months). The 2-year overall survival was 55.7%, with a median survival time of 29.9 months. In the univariate analysis, the maximal diameter ≤20 mm (P = 0.0383), solitary lesion (P = 0.0352), and the complete remission after treatment (P = 0.00411) had a significantly better prognosis. A total of 27 of 35 patients (77.1%) had progressive disease (loco-regional failure [n = 9], distant metastasis [n = 7], and both loco-regional failure and distant metastasis [n = 11]). No patients had Grade 3 or greater mucositis.
CONCLUSION: Local field radiotherapy is a considerable treatment option for postoperative loco-regional recurrence of esophageal cancer.
© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  esophageal cancer; loco-regional recurrence; postoperative recurrence; radiotherapy

Mesh:

Year:  2017        PMID: 28903531     DOI: 10.1093/jjco/hyx092

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  4 in total

1.  Involved-field chemoradiotherapy for postoperative solitary lymph node recurrence of esophageal cancer.

Authors:  Terufumi Kawamoto; Keiji Nihei; Keisuke Sasai; Katsuyuki Karasawa
Journal:  Esophagus       Date:  2018-05-30       Impact factor: 4.230

2.  Outcomes and Prognostic Factors of Salvage Radiation for Postoperative Lymph Node Recurrence of Esophageal Squamous Cell Carcinoma.

Authors:  Chi Zhang; Xiao-Lin Ge; Chen-Jun Huang; Shu Zhang; Xin-Chen Sun
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

3.  Adjuvant Radiotherapy of Involved Field versus Elective Lymph Node in Patients with Operable Esophageal Squamous Cell Cancer: A Single Institution Prospective Randomized Controlled Study.

Authors:  Ruifeng Liu; Xueliang Zhang; Qiuning Zhang; Hongtao Luo; Shihong Wei; Tingting Liu; Shilong Sun; Zhiqiang Liu; Zheng Li; Jinhui Tian; Xiaohu Wang
Journal:  J Cancer       Date:  2021-03-31       Impact factor: 4.207

4.  Arterial Infusion Chemotherapy for Neoplastic Esophagogastric Anastomotic Strictures After Esophagectomy.

Authors:  Pengfei Xie; Meipan Yin; Wei He; Yaozhen Ma; Chunxia Li; Zhen Li; Xiaobing Li; Shuai Wang; Gang Wu
Journal:  Front Oncol       Date:  2021-05-26       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.